(ACOG)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
| Name | Position |
|---|---|
| Dr. Denis G. Kay M.Sc., Ph.D. | Chief Scientific Officer |
| Mr. Henry Du CPA | VP of Finance & Accounting and Interim CFO |
| Mr. Jack Kelly | Executive Director & Head of Market Access |
| Mr. Kenneth Anthony Cawkell B.A., LL.B. | Founder, Consultant, Corporate Secretary & Director |
| Mr. Michael E. McFadden B.B.A. | CEO & Director |
| Mr. Timothy Ayers | Head of Compliance |
| Ms. Amy Kincaid | Executive Director, Head of Marketing & Commercial Strategy |
| Date | Type | Document |
|---|---|---|
| 2026-01-15 | 8-K | ea027312401-8k_alpha.htm |
| 2026-01-13 | S-8 | ea0272417-s8_alpha.htm |
| 2025-11-13 | 10-Q | ea0263490-10q_alpha.htm |
| 2025-10-15 | 8-K/A | ea026130201-8ka_alphacog.htm |
| 2025-10-14 | 8-K | ea0261254-8k_alpha.htm |
| 2025-10-02 | 8-K | ea0259660-8k_alpha.htm |
| 2025-08-28 | CORRESP | filename1.htm |
| 2025-08-22 | 8-K | ea0254408-8k_alphacog.htm |
| 2025-08-14 | 10-Q | ea0250497-10q_alpha.htm |
| 2025-07-23 | CORRESP | filename1.htm |
| Ms. Lauren D'Angelo M.B.A. |
| Chief Operating Officer |